A THERAPEUTIC VACCINE FOR EBV-ASSOCIATED MALIGNANCIES

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 这一试点计划旨在探索对慢性感染爱泼斯坦-巴尔相关病毒(EBV)的猴子进行治疗性疫苗接种是否能够更好地控制这种病毒。EBV是一种病毒，感染95%的成年猕猴和人类，并可能导致免疫受损的人患上癌症。该疫苗将使用一种新的载体，该载体基于一种来自黑猩猩的腺病毒的复制缺陷版本，人类对这种病毒没有预先存在的免疫力。这一试点应用的结果将导致研制出一种人类疫苗，以预防或限制感染人类免疫缺陷病毒(HIV)的患者或器官移植接受者的癌症发生。 该提案要求根据Elispot反应和唾液中潜在的病毒存在来识别12只曾接触过恒河猴EBV的恒河猴。然后，这些动物将接受表达恒河猴EBNA1的黑猩猩Adeno68或EBNA1和HSVgD的融合的单一免疫。免疫反应和病毒脱落的潜在证据将被描绘出来。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. This pilot program is designed to explore whether therapeutic vaccination of monkeys chronically infected with Epstein-Barr related virus (EBV, a virus that infects 95% of adult macaques and humans and can lead to cancer in immunoimpaired individuals) can result in better control of this virus. The vaccine will use a novel vector based on a replication defective version of an adenovirus derived from chimpanzees and for which humans do not have pre-existing immunity. Findings from this pilot application will lead to the formulation of a human vaccine to prevent or limit the occurrence of cancer in patients infected with human immunodeficiency virus (HIV) or recipients of organ transplant. The proposal calls for the identification of 12 rhesus macaques with prior exposure to rhesus EBV based on ELISPOT responses and potential presence of virus in the saliva. These animals will then undergo a single immunization with a Chimp adeno68 expressing rhesus EBNA1 or a fusion of EBNA1 and HSVgD. Immune responses and potential evidence of virus shedding will be delineated.